- ►uab.edu [PDF] WM Lee - The New England journal of medicine, 2003 - nejm.highwire.org In the past five years, two drugs have been withdrawn from the market by the
Food and Drug Administration (FDA) for causing severe liver injury, a potential
danger that had not been fully recognized in the course of the preapproval ... Cited by 665 - Related articles - BL Direct - All 22 versions
BA Neuschwander-Tetri, EM Brunt, KR … - Journal of hepatology, 2003 - Elsevier Background/Aims: Hyperinsulinemia may cause hepatic steatosis and non-alcoholic
steatohepatitis (NASH). The aims of this pilot study were to examine the safety
of using the insulin-sensitizing peroxisomal proliferator activated ... Cited by 95 - Related articles - All 11 versions
- ►oxfordjournals.org CJ Glueck, A Moreira, N Goldenberg, L Sieve … - Human Reproduction, 2003 - ESHRE BACKGROUND: In an observational study of 13 women with polycystic ovary syndrome
(PCOS) not optimally responsive to metformin diet, we assessed the efficacy and
safety of addition of pioglitazone. We also compared these 13 women to 26 ... Cited by 75 - Related articles - BL Direct - All 8 versions
GE Dailey, MA Noor, JS Park, S Bruce, FT … - The American journal of medicine, 2004 - Elsevier Following an open-label, lead-in phase to optimize the dosing of
glyburide/metformin tablets, 365 patients randomly received additive therapy
comprising rosiglitazone (4 mg once daily) or placebo for 24 weeks. Based ... Cited by 64 - Related articles - All 9 versions
- ►adisonline.com [PDF] J Waugh, GM Keating, GL Plosker, S … - Drugs, 2006 - ingentaconnect.com 0012-6667/06/0001-0085/$44.95/0 2006 Adis Data Information BV. All rights
reserved. ... A Review of its Use in Type 2 Diabetes Mellitus ... John Waugh,
Gillian M. Keating, Greg L. Plosker, Stephanie Easthope and Dean M. Robinson Cited by 64 - Related articles - BL Direct - All 7 versions
WL Isley - eds, 2003 - informahealthcare.com Thiazolidinediones are insulin sensitisers now widely used for the treatment of
Type 2 diabetes mellitus. The initial marketed drug in this class, troglitazone,
was removed from the market worldwide after approximately 3 years of use ... Cited by 53 - Related articles - BL Direct - All 9 versions
KG Tolman, J Chandramouli - Clinics in Liver Disease, 2003 - Elsevier Type II diabetes mellitus is a chronic metabolic disorder characterized by
hyperglycemia secondary to inadequate insulin secretion. The earliest detectable
abnormality is peripheral insulin resistance, leading to impaired uptake of ... Cited by 52 - Related articles - BL Direct - All 2 versions
- ►aspetjournals.org J Sahi, CB Black, GA Hamilton, X Zheng, S … - Drug Metabolism and Disposition, 2003 - ASPET Rosiglitazone and pioglitazone are thiazolidinediones used for treatment of
noninsulin-dependent diabetes mellitus. These compounds, along with
troglitazone, were evaluated for the ability to induce cytochrome P450 ... Cited by 54 - Related articles - BL Direct - All 5 versions
- ►annals.org [PDF] KG Tolman, V Fonseca, MH Tan, A Dalpiaz - Annals of internal medicine, 2004 - Am Coll Physicians Diabetes mellitus is the fifth leading cause of death in the United States; 17
million people are affected. Liver disease is one of the leading causes of death
in persons with type 2 diabetes. The standardized mortality rate for death ... Cited by 51 - Related articles - All 5 versions
